Allena Pharmaceuticals, Inc. Shares (Diluted, Weighted)

Shares (Diluted, Weighted) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Shares (Diluted, Weighted) growth rates and interactive chart. Number of diluted weighted average common shares outstanding in a company.

Highlights and Quick Summary

  • Shares (Diluted, Weighted) for the quarter ending March 31, 2022 was $89.4 Million (a 7.73% increase compared to previous quarter)
  • Year-over-year quarterly Shares (Diluted, Weighted) increased by 54.29%
  • Annual Shares (Diluted, Weighted) for 2021 was $68 Million (a 109.05% increase from previous year)
  • Annual Shares (Diluted, Weighted) for 2020 was $32.5 Million (a 46.55% increase from previous year)
  • Annual Shares (Diluted, Weighted) for 2019 was $22.2 Million (a 6.94% increase from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Shares (Diluted, Weighted) of Allena Pharmaceuticals, Inc.

Most recent Shares (Diluted, Weighted)of ALNA including historical data for past 10 years.

Interactive Chart of Shares (Diluted, Weighted) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Shares (Diluted, Weighted) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $89.38 – – – –
2021 $82.97 $76.66 $57.93 $55.02 $67.96
2020 $42.0 $36.26 $26.88 $24.74 $32.51
2019 $22.18 $23.47 $20.9 $20.82 $22.18
2018 $20.74 $20.75 $20.73 $20.7 $20.74
2017 $4.52 $1.34 $1.34 $1.34 $4.52
2016 – – – $1.34 $1.34
2015 – – – – $1.26

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
© stockrow.com